RIX 4414 shows safety and immunogenicity in infants

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1664, 2008-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rotavirus Vaccine RIX4414 (Rotarix™)

By Keating Gillian M.

Pediatric Drugs, Vol. 8, Iss. 6, 2006-01 ,pp. : 389-395

Adis International

Access to resources Recommend Favorite

Rotavirus Vaccine RIX4414 (Rotarix™): A Viewpoint by David I. Bernstein

By Bernstein David I.

Pediatric Drugs, Vol. 8, Iss. 6, 2006-01 ,pp. : 396-397

Adis International

Access to resources Recommend Favorite

Rotavirus Vaccine AVANT Immunotherapeutics/GlaxoSmithKline: 89-12, RIX4414

By Adis International Limited

Drugs in R&D, Vol. 5, Iss. 2, 2004-01 ,pp. : 113-115

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries†

By Plosker Greg L.

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 239-244

Adis International

Access to resources Recommend Favorite

The rotavirus vaccine Rotarix [RIX 4414] is to be introduced in the UK in September 2013

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 667, 2012-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite